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Abstract
Background:  Pituitary tumor transforming gene (PTTG), also known as securin, is highly
expressed in various tumors including pituitary, thyroid, colon, ovary, testis, lung, and breast. An
overexpression of PTTG enhances cell proliferation, induces cellular transformation in vitro, and
promotes tumor development in nude mice. PTTG also inhibits separation of sister chromatids
leading to aneuploidy and genetic instability. A great amount of work has been undertaken to
understand the biology of PTTG and its expression in various tumors. However, mechanisms by
which PTTG mediates its tumorigenic function are not fully understood. To utilize this gene for
cancer therapy, identification of the downstream signaling genes regulated by PTTG in mediation
of its tumorigenic function is necessary. For this purpose, we expressed PTTG in human embryonic
kidney (HEK293) cells that do not express PTTG and analyzed the downstream genes using
microarray analysis.
Results: A total of 22,277 genes printed on an Affymetrix HG-U133A 2.0 GeneChip™ array were
screened with labeled cRNA prepared from HEK293 cells infected with adenovirus vector
expressing PTTG cDNA (AdPTTG cDNA) and compared with labeled cRNA prepared from
HEK293 cells infected with control adenovirus (control Ad) or adenovirus vector expressing GFP
(AdGFP). Out of 22,277 genes, 71 genes were down-regulated and 35 genes were up-regulated
with an FDR corrected p-value of ≤ 0.05 and a fold change of ≥2. Most of the altered genes
identified are involved in the cell cycle and cell apoptosis; a few are involved in mRNA processing
and nitrogen metabolism. Most of the up-regulated genes belong to the histone protein family.
Conclusion: PTTG is a well-studied oncogene for its role in tumorigenesis. In addition to its
importance in regulation of the cell cycle, this gene has also been recently shown to play a role in
the induction of cell apoptosis. The microarray analysis in the present study demonstrated that
PTTG may induce apoptosis by down-regulation of oncogenes such as v-Jun and v-maf and up-
regulation of the histone family of genes.
Background
Pituitary tumor transforming gene (PTTG) is a multifunc-
tional protein involved in the cell cycle, cell proliferation,
angiogenesis, metastasis, and other cellular functions.
PTTG was initially isolated from rat pituitary tumor [1].
Based on its function in the inhibition of separation of sis-
ter chromatids, it was named securin [2]. Overexpression
of PTTG was reported in many cancers including ovary,
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lung, testis, kidney, colon, thyroid, pituitary, liver, adre-
nal, breast, prostate, melanoma, leukemia, and lym-
phoma [3-15]. Many laboratories have explored this
oncogene for its role in tumorigenesis since its identifica-
tion (see reference [16] for review). Pei and Melmed [1]
showed that overexpression of PTTG in NIH3T3 cells
inhibits cell proliferation and induces cell transformation
in vitro. In contrast, overexpression of PTTG in human
embryonic kidney (HEK293) cells was shown to increase
cell proliferation, induce cellular transformation in vitro,
and promote tumor development in nude mice [7,17].
Ishikawa et al. [18] and McCabe et al. [19] showed PTTG's
role in angiogenesis by coinciding its function in inducing
the expression of basic fibroblast growth factor (bFGF)
and vascular endothelial cell growth factor (VEGF).
Heaney et al. [20] reported regulation of PTTG expression
in vitro and in vivo by estrogen. Ishikawa et al. [18] dem-
onstrated that the conditioned medium collected from
NIH3T3 cells overexpressing human PTTG induced angio-
genesis through up-regulation of bFGF both in vitro and in
vivo. This information was further confirmed by Kim et al.
[21] who showed regulation of angiogenic genes such as
ID3 and TSP-1 by PTTG. Angiogenic gene ID3 has been
shown to be up-regulated by VEGF [22], which is believed
to play a critical role in cell proliferation and to be a pre-
cursor of endothelial cell recruitment [23,24]. Shibata et
al. [25] showed the importance of PTTG in tumor metas-
tasis and its correlation with the pathological stage, levels
of pain, and extensive lymph node metastasis in esopha-
geal cancer patients. Its expression levels were found to be
correlated with a higher degree of tumor recurrence and
tumor aggression in breast cancer as well as in squamous
cell carcinoma [26,27]. In our previous studies, we [28]
demonstrated the up-regulation of matrix metalloprotein-
ase (MMP)-2 and its relationship in tumor angiogenesis
and metastasis.
Role of PTTG in tumorigenesis was further confirmed by
down-regulation of PTTG in tumors. Chen et al[29]
down-regulated PTTG expression using full-length anti-
PTTG complementary (c) DNA in SKOV3 and showed a
significant reduction of cell proliferation and colony for-
mation on soft agar compared to the non-transformed
cells and bFGF protein levels. In this context, using PTTG
siRNA to transfect an ovarian tumor cell line (A2780), El-
Naggar et al. [30] showed a 50% reduction in cell prolif-
eration and a 70% reduction in colony formation. In
addition, these investigators demonstrated a reduced inci-
dence of tumor development and tumor growth in nude
mice injected with A2780 cells that constitutively
expressed PTTG siRNA compared to cells expressing con-
trol siRNA. These results were confirmed by Cho-Rok et al.
[31] using an adenovirus expression system expressing
PTTG siRNA in a hapotoma cell line.
The molecular mechanisms by which PTTG achieves its
functions remain unclear. Although a limited number of
individual target genes in various cell lines have been
identified, a large-scale profile of the target genes regu-
lated by PTTG had not been undertaken at the time of this
study. For this purpose, we explored the cDNA-microarray
technology to identify the differentially expressed genes
by PTTG. Most of the tumors and cancer cell lines overex-
press PTTG; therefore, we selected HEK293 cells, which
expresses a very low or undetectable level of endogenous
PTTG. The change in expression of some genes by PTTG
identified by cDNA microarray analysis was confirmed by
quantitative real-time PCR (qRT-PCR).
Methods
Cell lines
HEK293 cells were propagated in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) according to instructions from Amer-
ican Type Culture Collection (ATCC; Manassas, VA).
Medium and serum were purchased from Invitrogen
(Carlsbad, CA). Cells were grown under 5% CO2 at 37°C.
Plasmid construct
The full length PTTG cDNA was sub-cloned into adenovi-
rus shuttle vector pShuttle. Positive clones were
sequenced to confirm the sequence and orientation of
cDNA. The adenovirus expression system was generated
and purified in association with the Gene Therapy Center,
Virus Vector Core Facility, University of North Carolina at
Chapel Hill.
Expression of PTTG in HEK293 cells using the adenovirus 
expression system
HEK293 cells growing in log phase were trypsinized and
plated on T-75 flasks. Cells were infected with adenovirus
vector, adenovirus vector expressing GFP (AdGFP), or ade-
novirus vector expressing PTTG cDNA (AdPTTG cDNA) at
variable multiplicities of infection (MOI). Infection of
cells was carried out in serum-free DMEM medium for 2
h. After 2 h, the medium was replaced with regular growth
medium and incubated at 37°C under 5% CO2. The opti-
mum MOI was found to be 1:10 to provide a 90- to 95%
level of infection. Experiments were performed in accord-
ance with instructions from the University of Louisville
Institutional Biosafety Committee.
Isolation of total RNA
After 48 h of post-infection with adenovirus at a MOI of
1:10, medium was aspirated and cells were rinsed twice
with phosphate-buffered saline (PBS). Cells were har-
vested by scraping with a rubber policeman and centri-
fuged at 5000 rpm for 5 min. The medium was discarded
and 1 ml of Triazol reagent (Sigma-Aldrich, St. Louis,
MO) was added to the cell pellet. The cells were homoge-BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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nized and total RNA was purified as described previously
[7]. Quality of RNA was examined on agarose gel electro-
phoresis and quantified by NanoDrop 1000 (Thermo Sci-
entific, Waltham, MA). All treatments were performed in
triplicate.
Western blot analysis
Cells were cultured in complete growth media to 80-90%
confluence. Cells were washed and collected in cold PBS
and lysed with lysis buffer (10 mM Tris-HCl, pH 7.5; 150
mM NaCl; 1% Triton X-100; 1 mM EDTA). Protein con-
centration for each sample was assayed by Bradford
Method (Bio-Rad Laboratories). Forty micrograms of pro-
tein from each sample was resolved on 15% SDS polyacr-
ylamide gel and transferred to nitrocellulose membranes
(GE Healthcare Biosciences, Piscataway, NJ). Membranes
were blocked overnight with 5% non-fat milk/Tween (20
mM Tris/HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6)
(TBST). Membranes were incubated with PTTG antiserum
diluted at (1:1,500) [32] for 1 h at room temperature fol-
lowed by 3 washes with TBST and then incubated with
HRP-conjugated goat anti-rabbit secondary antibody
diluted at 1:5,000. The immune complexes formed were
detected by ECL reagents (GE Healthcare Biosciences).
The blots were stripped and reprobed with β-actin anti-
body (Sigma-Aldrich, USA.) to examine equal loading.
Microarray analysis
The microarray analysis was performed at the University
of Louisville Microarray Core Facility according to instruc-
tions from Affymetrix (Santa Clara, CA). mRNA was con-
verted into double stranded cDNA using a T7-oligo (dT)
promoter primer sequence. The double-stranded cDNA
was purified and served as a template in the subsequent in
vitro transcription reactions. The in vitro transcription reac-
tions were carried out in the presence of T7 RNA polymer-
ase and a biotinylated nucleotide analog/ribonucleotide
mix for cRNA amplification. The biotinylated cRNA was
purified, fragmented, and used in the hybridization cock-
tail containing control oligonucleotide B2 and four con-
trol bacterial and phage cDNA (BioB, BioC, BioD, cre).
The labeled cRNA was hybridized to GeneChip expression
arrays Human U133A 2.0 (Affymetrix), containing 22,277
genes using the protocol described by Affymetrix and as
described previously [33]. Alterations in RNA transcript
levels (AdPTTG cDNA vs. adenovirus or adenovirus vs.
AdGFP) were analyzed using Partek Genomics Suite 6.2
(Partek Inc., St. Louis, MO). Three different experiments
were performed for statistical analysis.
Data analysis
Data analysis was performed using Partek Genomics Suite
6.2 (Partek Inc., St. Louis, MO). The Affymetrix probe
level signal values were summarized using the RMA algo-
rithm. Statistically significant changed genes were identi-
fied by analysis of variance (ANOVA) with FDR-corrected
p-values < 0.05. The contrast between adenovirus vs.
AdGFP yielded no significantly different in genes based
on these parameters. Two-way ANOVA tests were carried
out to identify differentially expressed genes in the com-
parison of AdPTTG cDNA vs. adenovirus, taking treatment
and batch effect for the triplicate sample processing into
account. The genes that showed 2-fold induction or 2-fold
suppression were transferred to separate up and down
lists, respectively. The gene sets with an FDR corrected p-
value of less than 0.05 were identified in these lists and
Ingenuity Pathway Analysis software (Ingenuity Systems
Inc., Redwood City, CA) was used to interpret the interac-
tive pathway networks between the selected genes from
the microarray data.
qRT-PCR analysis
The genes that showed signal detection values more than
100, p-values less than 0.001, and a change in gene
expression of more than 2-fold when compared to the
control were selected to study their relative expressions by
qRT-PCR using a MyiQ single color real-time PCR detec-
tion system (Bio-Rad Laboratories, Hercules, CA). qRT-
PCR was performed in a total of 20 μl reaction volume
containing 1 μl of cDNA, 1 μl each of forward- and
reverse-specific primers (from 10 μM primer stock), 10 μl
of supermix (Bio-Rad Laboratories), and 7 μl of nuclease-
free water. All qRT-PCR reactions were performed using
the following reaction conditions: initial denaturation at
95°C for 3 min followed by 45 cycles at 95°C for 10 s,
60°C for 20 s, and 72°C for 30 s. A fluorescence reading
determined the extent of amplification at the end of each
cycle.
Standard curves were obtained using a 10-fold serial dilu-
tion of pooled cDNA from all treatments. Expression of
the human glyceraldehyde phosphate dehydrogenase
(GAPDH) gene was used for normalization of data. For all
candidate genes (Table 1), the quantities of the mRNA
expression relative to GAPDH were obtained. All samples
were measured in triplicate. The PCR efficiency and corre-
lation coefficient values were taken into account before
estimating the relative expression. Mean and standard
errors for each treatment were obtained from all three rep-
licates and each experiment was repeated at least twice.
Results and Discussion
Adenovirus infection showed 90% efficiency
The pShuttle vector carrying a full-length PTTG sequence
was used in this study. A control adenovirus (control Ad)
and AdGFP were used as controls. All three purified aden-
ovirus constructs were used to infect HEK293 cells at var-
iable MOIs to optimize a high level of infection. All the
infected cells were examined for GPF expression after 24 h
of infection (Fig. 1). The cells infected with AdGFPBMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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showed almost 95% level of infection at MOI of 1:10.
Expression of PTTG was examined using Western blot
analysis as described previously [32]. As shown in Fig. 2,
a high level of expression of PTTG protein was observed in
HEK293 cells infected with AdPTTG cDNA at 48 h post-
infection.
PTTG overexpression caused down-regulation of many 
genes
The microarray analysis of the human genome chip con-
taining 22,277 genes showed a total of 106 genes differen-
tially expressed in the experimental group, within an FDR
corrected p-value ≤ 0.05 and fold change of ≥2 (Table 2).
Among these 106 genes, 71 genes were down-regulated
and 35 genes were up-regulated (additional file 1). The
microarray data was deposited in public repository,
ArrayExpress (http://www.ebi.ac.uk/arrayexpress, acces-
sion # E-MEXP-2449). The majority of the genes that were
down-regulated belong to transcriptional factors, DNA
binding proteins, and other interacting proteins involved
in Wnt and Notch signaling pathways. Among the up-reg-
ulated genes, majority of genes belong to the histone pro-
tein family. Seven genes with the lowest p-values (≤
0.0005) and high fold change (3 to 20) including PTTG,
v-Jun and v-maf, H1c, H2be, H2bo, and H2ac were vali-
dated by qRT-PCR.
v-Jun and Maf were down-regulated in PTTG-expressed 
HEK293 cells
The microarray analysis of HEK293 cells infected with
AdPTTG cDNA showed significant down-regulation of the
oncogene v-Jun. This gene was initially identified as the
oncogenic factor of avian sarcoma virus 17 (ASV17) [34].
The cellular homologue of v-Jun is c-Jun, which is a pre-
dominant component of AP-1 transcriptional factors. The
c-Jun oncogene can form homodimers and also forms
heterodimers with Fos family members. This complex
binds to TPA-response elements [34] and regulates a
diverse range of biological functions ranging from cell
growth and differentiation to stress signaling pathways
Table 1: The primer sequences used for the validation of differentially expressed genes by PTTG overexpression through qRT-PCR.
S. No Gene name Forward Primer Reverse primer
1 PTTG 5' gccttagatgggagatctca 3' 5' gctttaacagtcttctcagt 3'
2 v-jun 5' gcgtgcgctcttagagaaac 3' 5' ccgttgctggactggattat 3'
3 v-maf 5' cccgaccgaacagaagac 3' 5' gcttggtgatgatggtgatg 3'
4 H2be 5' ccgcaaagagagctactcca 3' 5' ggagctggtgtacttggtga 3'
5 H1c 5' agcgtagcggagtttctctg 3' 5' tagcgctcttcttcggagtt 3'
6 H2bo 5' gcagccgcaaagagacttac 3' 5' tggagctggtgtacttggtg 3'
7 H2ac 5' agaagaacaacagccgcatc 3' 5' gcttcttcgccttctttgg 3'
Expression of AdGFP Figure 1
Expression of AdGFP. HEK293 cells were infected with 
AdGFP protein after 24 h post-infection.
Western blot analysis of PTTG protein expression in  HEK293 cells infected with empty adenovirus, adenovirus  with GFP and adenovirus with PTTG cDNA Figure 2
Western blot analysis of PTTG protein expression in 
HEK293 cells infected with empty adenovirus, adeno-
virus with GFP and adenovirus with PTTG cDNA.BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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[35]. The biochemical studies on c-Jun showed that this
gene negatively regulates the association of p53 with
p21CIP1 gene promoter [36]. Experiments by Maclaren
[37] showed that the mRNA and protein levels of
p21CIP1 were greatly reduced by v-Jun in chicken embryo
fibroblasts (CEFs). They also found that the repression of
p21CIP1 occurs by both p53-dependent and -independ-
ent mechanisms. The cell cycle regulator p21CIP1 is a
cycle-dependent kinase inhibitor, which arrests the cell
cycle throughout the G1/S phase. The present study
showed down-regulation of v-Jun by overexpression of
PTTG in HEK293 cells in both microarray and qRT-PCR
analyses (Fig. 3 and 4). The microarray data showed a
down-regulation of this gene by 3.86-fold. The qRT-PCR
analysis of this gene showed 4.2-fold down-regulation,
which is in directional correspondence with the microar-
ray data. From these observations, we believe that overex-
pression of PTTG may induce p21CIP1 by down-
regulating its inhibitor v-Jun. There are also reports that
the p21CIP1 promoter is activated by a tumor-suppressor
gene p53 [38]. Our microarray data also showed a slight
up-regulation of p53 by PTTG-over expression (data not
shown). In our previous studies, we showed up-regulation
of p53 transcription by PTTG [17]. There is evidence that
PTTG can induce expression of p21CIP1 [39], which is
also slightly up-regulated in our microarray data (results
not shown).
The Ingenuity Pathway analysis of the selected genes from
our microarray data showed that the oncogene Jun is
involved in the expression of hairy and enhancer of split
1 (Hes1) in Rat1a cells [40], which is reported to interact
with a dominant negative helix-loop-helix protein called
inhibitor of DNA binding 4 (ID4) [41]. Our microarray
data also showed the down-regulation of these two genes
(Hes1 and ID4), which might be the downstream targets
of Jun. In addition to these genes, Jun proteins are
involved in regulation of many genes such as cAMP,
cAMP-dependent protein kinase (Pka), insulin, cAMP
response element binding protein (CREB), VEGF, MAPK,
and ERK transcriptional factors (Fig. 5). The Ingenuity
Table 2: The differentially expressed genes with different p-values in PTTG-expressing HEK293 cells by microarray analysis.
S. No p-value Fold change Total genes Up-regulated Down-regulated
1 < 0.0001-0.0001 ≥22 5 1 0 1 5
2 >0.0001-0.001 ≥23 5 2 2 1 3
3 >0.001-0.01 ≥22 2 2 2 0
4 >0.01-0.05 ≥22 4 1 2 3
PTTG down-regulated Jun and Maf expression Figure 3
PTTG down-regulated Jun and Maf expression. A: 
Normalized expression of v-Jun and v-Maf in negative con-
trol, GFP control, and PTTG-overexpressed HEK293 cells by 
microarray analysis. The normalized expression values are 
mean ± SD (n = 3). The numbers above the bar represent 
the fold change of treatment with control group.
PTTG down-regulated Jun and Maf expression Figure 4
PTTG down-regulated Jun and Maf expression. B: The 
relative expression of v-Jun and v-Maf in negative control, 
GFP control, and PTTG-overexpressed HEK293 cells by 
qRT-PCR. The relative expression values are mean ± SD (n = 
3). The numbers above the bar represent the fold change of 
treatment with control group.BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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pathway also showed that the PTTG1 induces expression
of human VEGF mRNA [42], whereas Jun represses VEGF
secretion [43]. Our previous studies on xenograft models
of HEK293 cells overexpressing PTTG1 by transiently in
nude mice induced the secretion of bFGF, VEGF and IL-8
protein levels significantly over the mice injected with
normal HEK293 cells [44]. We also identified the induced
expressions of VEGF, bFGF and IL-8 in the HEK293 cells
transiently transfected with PTTG1 cDNA in vitro. Similar
findings were also observed by other investigators where
PTTG was found to induce cell proliferation via VEGF, and
PTTG expression levels were always observed with the
induced levels of FGF and VEGF [45,46]. But the microar-
ray analysis of HEK293 cells overxpressing PTTG in the
present study did not show changes in VEGF, bFGF and
IL-8 transcripts significantly within the selected strin-
gency. Although we observed a slight increase in these
three transcripts (≤1.5-fold) they are filtered in the
selected stringent conditions (p-value ≤ 0.05 and ≥2-fold).
As we know that the cDNA-microarray can only provide
approximations of gene transcripts, which is further asso-
ciated with some experimental noises that detracts the
experiment ability, we expect loss or gain of signal inten-
sities. Also the previous studies showed the expression of
VEGF and FGF by PTTG in transient transfection experi-
ments, which express moderate levels of PTTG protein.
Whereas in the present study we utilized adenoviral medi-
ated expression of PTTG, which yields higher levels of
PTTG protein expressions, which could be an additional
possibility of variation in the experimental data. PTTG
being an important protein involved in various cellular
pathways, from the present study we also observed that
the influence of PTTG on various cell signaling is more of
quantitative than generic. From these observations, it may
The Ingenuity pathway analysis of differentially expressed genes interlinked with the v-Jun regulation by PTTG Figure 5
The Ingenuity pathway analysis of differentially expressed genes interlinked with the v-Jun regulation by 
PTTG.BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
Page 7 of 12
(page number not for citation purposes)
be possible that PTTG is involved in angiogenesis both by
inducing expression of angiogenic factors such as VEGF
and bFGF as well as by the down regulation of transcrip-
tional factors that repress the secretion of VEGF (Fig. 6).
The present study also showed the down-regulation of
another leucine zipper-bearing transcriptional factor, v-
Maf, by 4-fold in microarray data, which is consistent with
qRT-PCR analysis (Fig. 3 and 4). The recent findings also
suggest that mutated Jun, which lacks a transactivation
domain, represses cell transformation not only by itself,
but also by another oncogene, Maf [47]. From their stud-
ies, these investigators suggest that these two oncogenes
share downstream targets and induce cell transformation
through similar genes. Our studies showed a correlation
with these findings as both of these genes down-regulated
in microarray as well as in qRT-PCR. The ingenuity path-
way analysis showed that members of Maf gene transcrip-
tional factors regulate insulin gene transcription in islet
cells [48]. In turn, this was supported by the findings of
Wang et al. [49], who showed that PTTG knockout mice
severely impair glucose homeostasis leading to diabetes
during late adulthood due to impaired beta cell prolifera-
tion. From these observations, it is evident that PTTG has
its role in the cell cycle and tumorigenesis, but also is
involved in maintaining glucose homeostasis.
In addition to these relations, the Ingenuity pathway anal-
ysis (Fig. 7) also showed that the oncogene v-Myc is regu-
lated by MAPK, which in turn is regulated by c-Kit which
regulates human Slug (Snail 2) [50,51]. It was also known
that the oncogene Jun can be regulated by MAPK and
ERK[52]. Our microarray data also showed that along
with Jun and Myc, c-Kit and Slug were also down-regu-
lated. Slug (Snail 2) is a member of the snail family of
transcriptional factors, which is found to have a major
role in epithelial-mesenchymal transition (EMT). The
recent experiments on MDCK cell lines with Slug overex-
pression showed that this gene promotes EMT by induc-
ing discoid domain receptor (DDR)-2 expression [53].
Also, the studies of Vitali et al. [54] showed that the
knockout of Slug by RNAi facilitates apoptosis and inhib-
its invasive growth in neuroblastoma preclinical models.
From these findings, it can be concluded that the overex-
pression of PTTG can induce apoptosis either by inducing
expression of p21CIP1[39] or by inducting Bcl-2 expres-
sion [54].
Histone family of genes was up-regulated by PTTG 
overexpression
Long-term modifications in the chromatin may cause
changes in gene expression and there by regulate many
important cellular pathways. The fundamental unit of
chromatin, nucleosome, is composed of 146 bps of
genomic DNA wrapped by an octomer of the core histone
proteins H2a, H2b, H3, and H4. Each class of histone pro-
teins consists of several subtypes that are encoded by dif-
ferent genes. These genes show high similarity in sequence
Schematic diagram of PTTG's role in different pathways Figure 6
Schematic diagram of PTTG's role in different pathways.BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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and are synthesized during the S phase of the cell cycle.
The histone proteins in the nucleosome were also found
to have a direct role in execution of apoptosis [55]. His-
tone proteins can be modified to allow DNA to unwind
and permit transcriptional factor to bind and transacti-
vate. In addition to this, some modifications to histones
can inhibit transcriptional factor binding. For example
gene activation can be associated with histone acetylation
by histone acetyl transferase (HAT) [56], whereas histone
deacetylation by histone deacetylase (HDAC) can sup-
press gene expression. Also it was evident from the studies
that phosphorylation of histone is associated with activa-
tion of various immediate-early genes [57,58]. Also the
previous studies showed that methylation of arginine and
lysine residues can lead to gene activation and repression
respectively [59,60]. Though we found up-regulation of
these HAT and argentine methyltransferase in PTTG1
overexpressed HEK293 cells over normal/control cell line,
due to high p-value (0.2 and 0.4 respectively) we did not
validate them further by qRT-PCR analysis. The overex-
pression of PTTG in HEK 293 cells in the present study
also showed up-regulation of the histone family of genes
including H2bj, H1c, H2be, H2aa, H2bo, H2bh, H2bd,
H2bk, H2a, H2am, H2ac, and H3D. Out of these histone
genes, we have validated H2be, H1c, H2bo, and H2ac by
qRT-PCR analysis. All four of these histone genes showed
directional correspondence with the microarray data. The
microarray and qRT-PCR analysis of H2be, H2bo, H2ac,
and H1c (Fig. 8 and 9) showed up-regulation of these
genes in PTTG-infected cells indicating their possible role
in apoptosis. The ingenuity pathway analysis (Fig. 10)
showed that H1c is a cytochrome c-releasing factor that
appears in the cytoplasm in a p53-dependent manner
after irradiation and activates downstream destruction
programs [61]. The ingenuity pathway also showed that
HIRA can bind with Histine H2 [62]. HIRA is a homo-
logue of two cell cycle-regulated repressors of histone
gene expression in Saccharomyces cerevisiae, whose expres-
The Ingenuity pathway analysis of differentially expressed genes interlinked with the v-Maf regulation by PTTG Figure 7
The Ingenuity pathway analysis of differentially expressed genes interlinked with the v-Maf regulation by 
PTTG.BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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PTTG up-regulates Histone gene expressions Figure 8
PTTG up-regulates Histone gene expressions. A: 
Normalized expressions of H2be, H2bo, H2ac, and Hic in 
negative control, GFP control, and PTTG-overexpressed 
HEK293 cells by microarray analysis. Normalized expression 
values are mean ± SD (n = 3). The numbers above the bar 
represent the fold change of treatment with control group.
PTTG up-regulates Histone gene expressions Figure 9
PTTG up-regulates Histone gene expressions. B: The 
relative expression of H2be, H2bo, H2ac, and Hic in negative 
control, GFP control, and PTTG-overexpressed HEK293 
cells by qRT-PCR. The relative expression values are mean ± 
SD (n = 3). The numbers above the bar represent the fold 
change of treatment with control group.
The Ingenuity pathway analysis of differentially expressed genes interlinked with the Histone family gene regulation by PTTG Figure 10
The Ingenuity pathway analysis of differentially expressed genes interlinked with the Histone family gene regu-
lation by PTTG.BMC Genomics 2009, 10:577 http://www.biomedcentral.com/1471-2164/10/577
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sion blocks S-phase progression [63]. Although there is
not much known on the role of PTTG in histone regula-
tion, from the available literature it is evident that the
overexpression of PTTG can induce apoptosis by up-regu-
lating histone proteins. From these observations, we can
conclude that PTTG either choosing cellular proliferation
and tumorigenesis or p21CIP1-induced apoptosis
depends on its expression in a quantitative manner. As we
have previously used the adenovirus to infect cells, which
resulted in high expression of the gene, the data con-
firmed the induction of apoptosis. However, in the case of
lipid or chemical transfection methods, which can only
yield up to 70% transfection, showed the induction of cell
proliferation and tumorigenesis. This dual role of PTTG
therefore seems to be quantitative, making exploration of
this gene important for disease regulation.
Conclusion
PTTG is a well-known oncogene, which is found to be
expressed in many tumors and tumor cell lines. Existing
evidence shows that this gene is involved in cell prolifera-
tion, migration, tumor invasion, and metastasis. In addi-
tion to these tumorigenic functions, this gene plays an
important role in cell division. The recent findings of
PTTG in inducing apoptosis [39] brings forth a new role
for this gene in causing apoptosis rather than inducing cell
proliferation and tumorigenesis. To identify the differen-
tially expressed genes by PTTG overexpression in HEK293
cells, we have explored the oligonucleotide-microarray
and qRT-PCR techniques. Our data clearly indicate the
down-regulation of v-Maf and Jun and the up-regulation
of many histone genes, which may explain the pathways
by which PTTG induces apoptotic genes. In addition, the
fate of the cell that overexpresses PTTG to choose either a
tumorigenic or an apoptotic pathway may be based on its
quantity of expression, which reveals this gene as playing
dual roles.
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